- Home
- HCWB vs IMCC Comparison
HCWB vs IMCC Comparison
Compare HCWB & IMCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCWB
- IMCC
- Stock Information
- Founded
- HCWB 2018
- IMCC 1980
- Country
- HCWB United States
- IMCC Israel
- Employees
- HCWB N/A
- IMCC N/A
- Industry
- HCWB Biotechnology: Pharmaceutical Preparations
- IMCC Medicinal Chemicals and Botanical Products
- Sector
- HCWB Health Care
- IMCC Health Care
- Exchange
- HCWB Nasdaq
- IMCC Nasdaq
- Market Cap
- HCWB 10.8M
- IMCC 11.8M
- IPO Year
- HCWB 2021
- IMCC N/A
- Fundamental
- Price
- HCWB $4.31
- IMCC $2.63
- Analyst Decision
- HCWB Strong Buy
- IMCC
- Analyst Count
- HCWB 1
- IMCC 0
- Target Price
- HCWB $35.00
- IMCC N/A
- AVG Volume (30 Days)
- HCWB 112.9K
- IMCC 60.6K
- Earning Date
- HCWB 08-13-2025
- IMCC 08-12-2025
- Dividend Yield
- HCWB N/A
- IMCC N/A
- EPS Growth
- HCWB N/A
- IMCC N/A
- EPS
- HCWB N/A
- IMCC N/A
- Revenue
- HCWB $1,445,145.00
- IMCC $37,894,737.00
- Revenue This Year
- HCWB $178.36
- IMCC $47.12
- Revenue Next Year
- HCWB N/A
- IMCC $12.83
- P/E Ratio
- HCWB N/A
- IMCC N/A
- Revenue Growth
- HCWB N/A
- IMCC 12.68
- 52 Week Low
- HCWB $3.55
- IMCC $1.29
- 52 Week High
- HCWB $100.80
- IMCC $7.12
- Technical
- Relative Strength Index (RSI)
- HCWB 39.51
- IMCC 43.98
- Support Level
- HCWB $4.02
- IMCC $2.58
- Resistance Level
- HCWB $4.44
- IMCC $2.90
- Average True Range (ATR)
- HCWB 0.31
- IMCC 0.29
- MACD
- HCWB 0.06
- IMCC -0.08
- Stochastic Oscillator
- HCWB 11.95
- IMCC 20.97
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
About IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.